Abstract
Cervical cancer (CC) is a common gynecological malignancy for which prognostic and therapeutic biomarkers are urgently needed. The signature based on immune-related lncRNAs (IRLs) of CC has never been reported. This study is aimed at establishing an IRL signature for patients with CC. A cohort of 326 CC and 21 normal tissue samples with corresponding clinical information was included in this study. Twenty-eight IRLs were collected according to the Pearson correlation analysis between the immune score and lncRNA expression (p < 0.01). Four IRLs (BZRAP1-AS1, EMX2OS, ZNF667-AS1, and CTC-429P9.1) with the most significant prognostic values (p < 0.05) were identified which demonstrated an ability to stratify patients into the low-risk and high-risk groups by developing a risk score model. It was observed that patients in the low-risk group showed longer overall survival (OS) than those in the high-risk group in the training set, valid set, and total set. The area under the curve (AUC) of the receiver operating characteristic curve (ROC curve) for the four-IRL signature in predicting the one-, two-, and three-year survival rates was larger than 0.65. In addition, the low-risk and high-risk groups displayed different immune statuses in GSEA. These IRLs were also significantly correlated with immune cell infiltration. Our results showed that the IRL signature had a prognostic value for CC. Meanwhile, the specific mechanisms of the four IRLs in the development of CC were ascertained preliminarily.
Highlights
Cervical cancer (CC) is a malignant gynecologic tumor threatening the health of women
567 Long noncoding RNAs (lncRNAs) were highly expressed and 1428 lncRNAs were expressed at low levels in the CC samples (Table 1)
A total of 64 lncRNAs were obtained from the intersection of the two databases (Figure 1(a)), among which 10 lncRNAs were consistently upregulated and 54 lncRNAs were consistently downregulated in the two databases
Summary
Cervical cancer (CC) is a malignant gynecologic tumor threatening the health of women. The morbidity and mortality for CC rank fourth worldwide among women [1]. Infection with high-risk human papillomavirus (HPV), especially HPV16 and HPV18, is the main etiologic risk factor for CC and plays an important role in diagnostic tests [2]. Surgery is the main treatment method for CC in early stages while advanced-stage CC can be treated with radiotherapy, chemotherapy, or concurrent chemoradiation, thereby improving the survival rate of CC patients [3]. A considerable number of CC patients have poor prognosis due to metastasis or recurrence within two years after treatment [4]. Effective prevention to reduce morbidity and individual treatments to improve the prognosis of CC are important for obstetricians and gynecologists
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
